Published in Biomark Res on January 16, 2013
B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol (2013) 1.14
Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group. Clin Exp Metastasis (2014) 0.82
Comparative evaluation of the new FDA approved THxID™-BRAF test with High Resolution Melting and Sanger sequencing. BMC Cancer (2014) 0.78
Detection of Circulating BRAF(V600E) in Patients with Papillary Thyroid Carcinoma. J Mol Diagn (2015) 0.77
Improved Detection of Microsatellite Instability in Early Colorectal Lesions. PLoS One (2015) 0.77
BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients. PLoS One (2016) 0.77
Value of TIRADS, BSRTC and FNA-BRAF(V600E) mutation analysis in differentiating high-risk thyroid nodules. Sci Rep (2015) 0.77
Mutant B-Raf(V600E) Promotes Melanoma Paracellular Transmigration by Inducing Thrombin-mediated Endothelial Junction Breakdown. J Biol Chem (2015) 0.76
FCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma. DNA Cell Biol (2014) 0.76
Exploring the impact of EGFR T790M neighboring SNPs on ARMS-based T790M mutation assay. Oncol Lett (2016) 0.75
Validation of an NGS mutation detection panel for melanoma. BMC Cancer (2017) 0.75
A quantitative structure-activity relationship (QSAR) study of some diaryl urea derivatives of B-RAF inhibitors. Res Pharm Sci (2016) 0.75
Values of molecular markers in the differential diagnosis of thyroid abnormalities. J Cancer Res Clin Oncol (2016) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol (2008) 11.73
EGFR antagonists in cancer treatment. N Engl J Med (2008) 9.68
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res (2003) 8.67
BRAF mutations in hairy-cell leukemia. N Engl J Med (2011) 7.05
BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst (2003) 6.20
BRAF mutation in thyroid cancer. Endocr Relat Cancer (2005) 5.65
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab (2003) 4.93
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst (2009) 4.42
BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet (2004) 2.75
MAP kinases and the control of nuclear events. Oncogene (2007) 2.74
High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res (2003) 2.49
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol (2009) 2.48
BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol (2004) 2.21
Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J (2000) 2.17
Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn (2008) 1.80
Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors. J Mol Diagn (2009) 1.72
A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples. J Exp Clin Cancer Res (2010) 1.68
Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J (2004) 1.63
BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene (2005) 1.62
Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab (2004) 1.56
The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch Pathol Lab Med (2009) 1.56
Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res (2004) 1.47
Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E. Mol Cell Probes (2004) 1.39
Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders. J Mol Diagn (2007) 1.19
Detection of BRAF V600E mutation by pyrosequencing. Pathology (2008) 1.16
BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol (2006) 1.12
Clinical implication of highly sensitive detection of the BRAF V600E mutation in fine-needle aspirations of thyroid nodules: a comparative analysis of three molecular assays in 4585 consecutive cases in a BRAF V600E mutation-prevalent area. J Clin Endocrinol Metab (2012) 1.12
Optimized allele-specific real-time PCR assays for the detection of common mutations in KRAS and BRAF. J Mol Diagn (2010) 1.12
Therapeutic strategies for targeting BRAF in human cancer. Rev Recent Clin Trials (2007) 1.04
BRAFV600E detection in melanoma is highly improved by COLD-PCR. Clin Chim Acta (2011) 0.98
The V617F JAK2 mutation and the myeloproliferative disorders. Hematol Oncol (2005) 0.93
Allele specific locked nucleic acid quantitative PCR (ASLNAqPCR): an accurate and cost-effective assay to diagnose and quantify KRAS and BRAF mutation. PLoS One (2012) 0.89
Colorimetric approach to high-throughput mutation analysis. Biotechniques (2005) 0.87